Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Rising Doses of BI 1815368 in Healthy Males
NCT05857878Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1815368 in diabetic macular edema (DME) (7 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of patients treated who experience treatment-emergent adverse event assessed as drug-related up to 29 days. Started Jun 2023; status: completed.
02
Drugs
BI 1815368
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05857878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857878.